By Counterforce Health Team in Koselugo (selumetinib) —

How to Get Koselugo (Selumetinib) Covered by UnitedHealthcare in New York: Prior Authorization Forms, Appeal Scripts & Timelines

Answer Box: Fast Track to Koselugo Coverage in New York

For pediatric patients under 19 with NF1 and plexiform neurofibromas, UnitedHealthcare typically auto-approves Koselugo (selumetinib) based on age alone. If denied, you have strong appeal rights in New York through the Department of Financial Services external review process. First step today: Verify your child's age documentation and confirm your provider has submitted the UnitedHealthcare OptumRx prior authorization form with NF1 diagnosis codes (Q85.01). Most approvals process within 72 hours for pediatric cases.

Table of Contents

  1. What This Guide Covers
  2. Before You Start: Verify Your Coverage
  3. Gather Required Documentation
  4. Submit Your Prior Authorization Request
  5. Follow-Up Timeline and Scripts
  6. If You're Asked for More Information
  7. Appeals Process in New York
  8. Renewal and Reauthorization
  9. Quick Reference Checklist
  10. FAQ

What This Guide Covers

This guide helps families and healthcare providers navigate UnitedHealthcare's prior authorization process for Koselugo (selumetinib) in New York. Koselugo is FDA-approved for pediatric patients 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas.

Who this helps:

  • Parents and caregivers of children with NF1
  • Pediatric neurologists and oncologists
  • Specialty pharmacies handling Koselugo prescriptions
  • Patient advocates navigating insurance denials

Expected outcomes: Most pediatric cases under age 19 receive automatic approval. When denials occur, New York's robust external appeal process has helped overturn many specialty drug rejections with proper documentation.

Before You Start: Verify Your Coverage

Step 1: Confirm Your Plan Type

UnitedHealthcare operates several plan types in New York:

  • Commercial employer plans
  • Individual marketplace plans
  • Medicare Advantage
  • Medicaid managed care

Action needed: Check your insurance card for plan details and call the member services number to confirm Koselugo is covered under your specific formulary.

Step 2: Verify Network Status

Ensure your prescribing physician and preferred specialty pharmacy are in-network. Out-of-network providers may trigger additional prior authorization requirements.

Step 3: Check Formulary Tier

Koselugo typically requires prior authorization across all UnitedHealthcare formularies. Unlike many specialty drugs, step therapy is not required since Koselugo is first-in-class for pediatric NF1.

Gather Required Documentation

Essential Medical Records

Diagnosis Documentation (ICD-10: Q85.01):

  • Clinical confirmation of NF1 using NIH diagnostic criteria
  • At least two of: ≥6 café-au-lait macules, axillary/groin freckling, optic glioma, ≥2 Lisch nodules, bone dysplasia, or positive family history
  • Genetic testing results (if performed, though not required)

Plexiform Neurofibroma Evidence:

  • MRI or CT imaging showing inoperable tumors
  • Documentation of symptoms (pain, functional impairment)
  • Surgeon's assessment of resection risks/morbidity
  • Tumor measurements (≥3 cm in one dimension)

Required Safety Assessments

Before starting Koselugo, patients need:

  • Baseline echocardiogram to assess LVEF
  • Comprehensive ophthalmologic examination
  • Body surface area calculation (must be >0.55 m²)
Tip: Schedule these assessments early, as UnitedHealthcare may deny requests missing baseline cardiac and eye evaluations.

Clinical Documentation Checklist

  • Complete medical history and physical exam
  • Prior treatment attempts (if any)
  • Contraindications to surgery
  • Treatment goals and expected outcomes
  • Prescriber specialty (neurology or oncology preferred)

Submit Your Prior Authorization Request

For Patients Under 19 Years

Good news: UnitedHealthcare's 2024 policy states that Koselugo requests for patients under 19 years are often auto-approved based on age alone, bypassing detailed clinical review.

Standard Submission Process

  1. Provider submits PA form via UnitedHealthcare provider portal or fax
  2. Include all documentation from the checklist above
  3. Request expedited review if medically urgent (decision within 72 hours)
  4. Track submission using reference numbers provided

Key forms and portals:

Coverage at a Glance

Requirement Details Documentation Needed
Prior Authorization Required for all ages PA form submission
Age Eligibility 2+ years (auto-approval often <19) Birth certificate/medical records
Diagnosis NF1 with symptomatic, inoperable PN ICD-10 Q85.01, imaging, clinical notes
Step Therapy Not required N/A
Baseline Testing LVEF and eye exam Echocardiogram, ophthalmology report
Approval Duration 12 months initial and renewal Clinical response documentation

Follow-Up Timeline and Scripts

Expected Timelines

  • Standard review: 72 hours to 15 days
  • Expedited review: 24-72 hours
  • Pediatric cases (<19 years): Often same-day approval

Patient Phone Script

"Hi, I'm calling to check the status of a prior authorization for Koselugo for my child [name], member ID [number]. The request was submitted on [date] with reference number [if available]. Can you tell me the current status and if any additional information is needed?"

Follow-up questions:

  • "What specific documentation is missing?"
  • "Can this be expedited due to medical urgency?"
  • "What's the expected decision date?"

If You're Asked for More Information

Common Additional Requests

Medical Necessity Questions:

  • Detailed symptom documentation
  • Functional impact assessments
  • Photos or additional imaging
  • Second opinion consultations

Response Strategy: Work with your healthcare team to provide comprehensive responses quickly. UnitedHealthcare typically allows 14 days for additional information submission.

Clinician Corner: Medical Necessity Letter

Essential elements to include:

  • Specific NF1 diagnostic criteria met
  • Plexiform neurofibroma characteristics and location
  • Impact on daily functioning and quality of life
  • Why surgical resection isn't feasible
  • Expected treatment goals and monitoring plan
  • References to FDA labeling and clinical guidelines

Appeals Process in New York

New York offers some of the strongest patient appeal rights in the nation through the Department of Financial Services (DFS).

Internal Appeals (UnitedHealthcare)

Timeline: File within 180 days of denial Process: Submit through UnitedHealthcare member portal or by mail Decision time: 30 days (72 hours for expedited)

External Appeals (New York State DFS)

When to use: After receiving final adverse determination from UnitedHealthcare Timeline: File within 4 months of final internal denial Cost: $25 per appeal (waived for Medicaid or financial hardship) Decision time:

  • Standard: 30 days
  • Expedited: 72 hours (24 hours for non-formulary drugs)

Key advantage: DFS decisions are binding on UnitedHealthcare. If you win, the insurer must cover treatment and refund your appeal fee.

From our advocates: We've seen families succeed in New York external appeals by including peer-reviewed studies showing Koselugo's efficacy in pediatric NF1, along with detailed functional impact documentation. The independent medical reviewers assigned by DFS often have specialized knowledge that leads to overturned denials when clinical evidence is strong.

Appeal Script for Providers

"I'm requesting a peer-to-peer review for [patient name] regarding the Koselugo denial. This is a pediatric patient with confirmed NF1 and symptomatic plexiform neurofibromas that are inoperable due to [specific risks]. The denial appears to be based on [denial reason], but our documentation clearly shows [counterargument with evidence]."

Renewal and Reauthorization

When to Reapply

UnitedHealthcare typically approves Koselugo for 12-month periods. Begin renewal process 30-45 days before expiration.

Required Evidence for Renewal

  • Clinical response documentation: MRI showing stable or reduced tumor volume
  • Continued medical necessity: Ongoing symptoms or functional impairment
  • Safety monitoring results: LVEF assessments, ophthalmologic exams
  • No disease progression: Evidence that treatment remains beneficial

Success tip: Maintain detailed treatment logs and imaging schedules to streamline reauthorization.

Quick Reference Checklist

Before submitting:

  • Verify patient age and UnitedHealthcare plan type
  • Confirm NF1 diagnosis with ICD-10 code Q85.01
  • Obtain baseline LVEF and eye exams
  • Document inoperable plexiform neurofibromas
  • Complete UnitedHealthcare PA form

After submission:

  • Track reference number and submission date
  • Follow up within 72 hours if no response
  • Prepare appeal documents if denied
  • Schedule renewal 30-45 days before expiration

If denied:

  • File internal appeal within 180 days
  • Request peer-to-peer review
  • Prepare external appeal to NY DFS within 4 months
  • Gather additional clinical evidence as needed

FAQ

How long does UnitedHealthcare prior authorization take for Koselugo in New York? Pediatric cases under 19 often receive same-day approval. Standard cases take 72 hours to 15 days. Expedited reviews are completed within 24-72 hours.

What if Koselugo is non-formulary on my plan? Even non-formulary drugs can be covered through medical necessity appeals. New York's external appeal process is particularly effective for specialty medications with strong clinical evidence.

Does step therapy apply if my child tried treatments outside New York? No, Koselugo doesn't require step therapy since it's the only FDA-approved drug for pediatric NF1 with plexiform neurofibromas. Prior treatment history from any state should be accepted.

Can I request an expedited appeal in New York? Yes, if delay would jeopardize your child's health. Both UnitedHealthcare internal appeals and NY DFS external appeals offer expedited timelines with physician attestation of urgency.

What's the success rate for Koselugo appeals in New York? While specific statistics aren't published, New York's external appeal program has historically overturned many specialty drug denials when proper clinical documentation is provided.

Who can help me navigate this process in New York? Community Health Advocates (CHA) offers free insurance counseling at 888-614-5400. The NY Department of Financial Services also provides consumer assistance through their website.

About Counterforce Health: Counterforce Health specializes in turning insurance denials into successful appeals by analyzing denial letters, plan policies, and clinical notes to create targeted, evidence-backed rebuttals. Their platform helps patients, clinicians, and specialty pharmacies navigate complex prior authorization requirements and streamline the appeals process for medications like Koselugo.

For families dealing with UnitedHealthcare denials, Counterforce Health can help identify specific denial reasons and draft point-by-point responses aligned to the plan's own coverage rules, incorporating the right clinical evidence and procedural requirements for New York appeals.

Disclaimer: This guide provides general information about insurance coverage and appeals processes. It is not medical advice and should not replace consultation with your healthcare provider or insurance professional. Coverage policies and procedures may change. Always verify current requirements with UnitedHealthcare and New York state regulators.

Sources & Further Reading:

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.